Understanding the Link Between CKD-MBD and Cognitive Function in Children
Chronic Kidney Disease (CKD) in children is a serious condition that can impact various aspects of a child's life, including their cognitive abilities. Recent research from the Chronic Kidney Disease in Children (CKiD) Study has shed light on the association between CKD-Mineral Bone Disease (CKD-MBD) and cognitive function in children. This blog aims to help practitioners understand these findings and apply them to improve their skills and support children with CKD.
Key Findings from the CKiD Study
The study focused on 702 children with CKD and examined the relationship between biomarkers of bone and mineral metabolism and cognitive function. The key biomarker identified was fibroblast growth factor 23 (FGF-23), which was found to be associated with lower performance in cognitive tests, particularly those assessing attention regulation.
- Higher plasma FGF-23 levels were linked to poorer scores in tests measuring attention regulation, such as Conners' Continuous Performance Test II.
- Children in the highest FGF-23 tertile group had a 7% to 9% greater cognitive risk for attention-related tasks compared to those in the lowest tertile.
- Other biomarkers like 25(OH)D, 1,25(OH)2D, PTH, calcium, and phosphorus did not show significant associations with cognitive test scores.
Implications for Practitioners
For practitioners working with children with CKD, these findings highlight the importance of monitoring FGF-23 levels as part of the management strategy. Understanding the role of FGF-23 can help in identifying children at risk of cognitive impairment and implementing early interventions.
Here are some steps practitioners can take:
- Regularly assess cognitive function in children with CKD to identify any early signs of impairment.
- Consider FGF-23 levels as a potential marker for cognitive risk and tailor interventions accordingly.
- Collaborate with nephrologists to manage CKD-MBD effectively and minimize its impact on cognitive function.
- Encourage further research into the mechanisms by which FGF-23 affects cognitive function to develop targeted therapies.
Encouraging Further Research
While the CKiD study provides valuable insights, it also opens up avenues for further research. Understanding the long-term effects of elevated FGF-23 levels on cognitive function and exploring interventions to mitigate these effects are crucial next steps.
Practitioners are encouraged to stay informed about the latest research developments and consider participating in studies that explore innovative approaches to managing CKD-MBD and cognitive function in children.
Conclusion
The association between CKD-MBD and cognitive function in children is a critical area of study that can significantly impact educational and therapeutic strategies. By integrating these findings into practice, practitioners can better support children with CKD and help them achieve their full potential.
To read the original research paper, please follow this link: Association Between Chronic Kidney Disease–Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.
